Related Experiment Videos
[Soluble IL-2 receptor levels in rheumatic diseases]
M Takaya1, Y Ichikawa, H Shimizu
1Department of Internal Medicine, Tokai University School of Medicine, Kanagawa.
Ryumachi. [Rheumatism]
|June 1, 1993
Summary
Soluble interleukin-2 receptor (sIL-2R) levels are elevated in rheumatoid arthritis (RA) and Sjögren's syndrome (SS) patients, indicating lymphocyte activation. While not significantly increased in plasma for Behçet's disease (BD) patients, joint fluid sIL-2R levels were higher in BD and RA.
Area of Science:
- Immunology
- Rheumatology
- Biochemistry
Context:
- Soluble interleukin-2 receptors (sIL-2R) are biomarkers associated with immune system activation.
- Rheumatoid arthritis (RA), Sjögren's syndrome (SS), and Behçet's disease (BD) are inflammatory autoimmune conditions.
- Understanding immune activation markers can aid in disease diagnosis and management.
Purpose:
- To measure and compare plasma and joint fluid (JF) sIL-2R levels in patients with RA, SS, and BD.
- To investigate the correlation of sIL-2R levels with clinical and laboratory parameters in these diseases.
- To assess the extent of immune activation in the inflammatory lesions of these conditions.
Summary:
- Plasma sIL-2R levels were significantly elevated in RA and SS patients compared to healthy controls, but not in BD patients.
- Elevated sIL-2R levels were found in a higher percentage of RA and SS patients than BD patients.
- sIL-2R levels correlated with inflammatory markers in RA and SS, but not with disease activity in BD. JF sIL-2R levels were higher than plasma levels in RA and BD patients.
Impact:
- The findings suggest lymphocyte activation in RA and SS, and within inflammatory lesions in BD.
- sIL-2R may serve as a potential biomarker for immune activation in RA and SS.
- Immune activation appears relatively lower in BD compared to RA and SS, particularly in plasma.